Heinz Läubli (@LImmunotherapy) header
Heinz Läubli (@LImmunotherapy) profile picture

Cancer Immunotherapy changes Lives!

Basel
Joined September 2019
Photo by Heinz Läubli (@LImmunotherapy)Photo by Heinz Läubli (@LImmunotherapy)Photo by Heinz Läubli (@LImmunotherapy)Photo by Heinz Läubli (@LImmunotherapy)Photo by Heinz Läubli (@LImmunotherapy)
Heinz Läubli retweeted
🚨Review on TIM-3!🚨 science.org/doi/10.1126/scii… We all know TIM-3 is an important checkpoint molecule on T cells! *But* here we (Gonzalo & @KuchrooLab) review emerging evidence demonstrating unexpected roles for TIM-3 as a key regulator of myeloid cell function.
1
16
59
6,025
Great to see our paper published today in communications biology which reports ST3Gal1 to synthesise Siglec-7 and Siglec-9 ligands critical to maintaining immune suppression within the prostate TIME @EScottScience🥳 nature.com/articles/s42003-0…
7
8
2
37
6,229
Great work by Ronja Wieboldt and Natalia Mantuano in our lab @DepBiomedicine . They show that myeloid-derived suppressors are inhibiting efficient anti-tumor immunity by secreting CCL2 induced by sialic acid-Siglec interactions. #glycotime rdcu.be/dAt5I
1
1
7
917
Heinz Läubli retweeted
Pioneering chemist and Nobel Laureate Carolyn R. Bertozzi, PhD, FAACR, is excited about the new frontier of cancer therapies powered by chemistry. Learn how she is making an impact in this AACR Stories piece: bit.ly/3OKnqsw @CarolynBertozzi @Stanford_ChEMH #AACRFellows
1
3
5
2,676
New #JITC position article and guidelines: Corticosteroid-resistant immune-related adverse events: a systematic review bit.ly/3u0egRp @LImmunotherapy @AlfredZippelius @cappelliMD @DrJNaidoo
29
1
39
6,618
OPEN POSITION💡 The Cancer Immunotherapy group led by Heinz Läubli @LImmunotherapy is looking for a highly collaborative research associate with a goal-oriented mindset. Link Job offer: jobs.unibas.ch/offene-stelle…
4
5
655
David König presenting data from our BaseTIL trial combining tumor-infiltrating lymphocyte therapy with nivolumab at the #ESMOImmuno23
8
564
Interesting finding by @mikimannimiki and colleagues. Neu5Gc-containing lipids in the skin. #glycotime Detection of N-glycolyl-neuraminic acid-containing glycolipids in human skin frontiersin.org/articles/10.…
2
1
5
1,629
New #JITC article: Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors bit.ly/3ujIkao @MarkusJoerger @ElenaGarralda @LImmunotherapy
2
5
1,003
Heinz Läubli retweeted
Most antibody-based treatments for myeloid malignancies, including AML, result in myelotoxicity due to sharing of target antigens by human hematopoietic stem and progenitor cells (HSPCs). bit.ly/3tu4XZz  @UniSpitalBasel  @RominaMarone  @JekerLab
3
8
1,199